CHIEF FINANCIAL OFFICER APPOINTMENT

SYDNEY, Australia, 24 May 2013: Neuren Pharmaceuticals Limited (ASX: NEU) is pleased to announce that Mr Jon Pilcher will join the company as Chief Financial Officer and Company Secretary, based in Melbourne Australia, effective 19 August 2013. This appointment follows the Board’s recent decision to move Neuren’s investor relations and certain administrative functions to Australia. In his role, Jon will be working closely with Larry Glass, Neuren’s CEO, as well as Executive Chairman, Dr Richard Treagus.

Jon is currently Chief Financial Officer and Company Secretary of Acrux Limited (ASX: ACR) and has been a member of the leadership team for ten years. That period included Acrux’s IPO and listing on the Australian Securities Exchange, the development and FDA approval of three novel pharmaceutical products, as well as the landmark Axiron® licensing deal with Eli Lilly in 2010.

Jon is a qualified Chartered Accountant and holds a Bachelor of Science in Biotechnology from the University of Reading in the UK. He formerly spent seven years with international pharmaceutical groups, Medeva and Celltech (now part of UCB), based in the UK, where he held senior financial positions in the Research & Development and Corporate functions.

Commenting on his appointment, Richard Treagus said; “I am delighted that Jon has chosen to join the Neuren team at this very exciting time. We have a number of opportunities to progress as we aim to realise the full value of our product pipeline. Given his in-depth experience of growing pharma and biotech businesses, as well as his knowledge of the Australian capital markets, I have every confidence that Jon will make an immediate and very strong contribution to our company.”

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a publicly listed biopharmaceutical company focusing on the development of new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions such as Rett Syndrome and Fragile-X Syndrome as well as acute neurological injuries. Neuren presently has a clinical-stage molecule, NNZ-2566 in two Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development. Neuren currently has operations in New Zealand and the United States.
For more information, please contact:

Larry Glass, CEO
lglass@neurenpharma.com
Tel: +1 301 941 1830

Dr Richard Treagus, Executive Chairman
rtreagus@neurenpharma.com
Tel: +61 417 520 509